Lenalidomide - Nanexa AB
Alternative Names: NEX-20; NEX-20ALatest Information Update: 28 Oct 2025
At a glance
- Originator Nanexa
- Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell proliferation inhibitors; Immunomodulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for research development in Multiple-myeloma in Sweden (Parenteral)
- 07 Mar 2023 Chemical structure information added
- 06 Dec 2022 Nanexa AB plans a phase I trial for multiple myeloma (In Healthy Volunteers) (SC) (NCT05643248)